Anionic polysaccharides as delivery carriers for cancer therapy and theranostics: An overview of significance

dc.authorscopusidAli Zarrabi / 23483174100
dc.authorwosidAli Zarrabi / U-2602-2019
dc.contributor.authorSivakumar, Ponnurengam Malliappan
dc.contributor.authorZarepour, Atefeh
dc.contributor.authorAkhter, Sohail
dc.contributor.authorPerumal, Govindaraj
dc.contributor.authorKhosravi, Arezoo
dc.contributor.authorBalasekar, Premkumar
dc.contributor.authorZarrabi, Ali
dc.date.accessioned2025-04-17T11:00:09Z
dc.date.available2025-04-17T11:00:09Z
dc.date.issued2025
dc.departmentİstinye Üniversitesi, Mühendislik ve Doğa Bilimleri Fakültesi, Biyomedikal Mühendisliği Bölümü
dc.description.abstractRecently, cancer therapy has witnessed remarkable advancements with a growing focus on precision medicine and targeted drug delivery strategies. The application of anionic polysaccharides has gained traction in various drug delivery systems. Anionic polysaccharides have emerged as promising delivery carriers in cancer therapy and theranostics, offering numerous advantages such as biocompatibility, low toxicity, and the ability to encapsulate and deliver therapeutic agents to tumor sites with high specificity. This review underscores the significance of anionic polysaccharides as essential components of the evolving landscape of cancer therapy and theranostics. These polymers can be tailored to carry a wide range of therapeutic cargo, including chemotherapeutic agents, nucleic acids, and imaging agents. Their negative charge enables electrostatic interactions with positively charged drugs and facilitates the formation of stable nanoparticles, liposomes, or hydrogels for controlled drug release. Additionally, their hydrophilic nature aids in prolonging circulation time, reducing drug degradation, and minimizing off-target effects. Besides, some of them could act as targeting agents or therapeutic compounds that lead to improved therapeutic performance. This review offers valuable information for researchers, clinicians, and biomedical engineers. It provides insights into the recent progress in the applications of anionic polysaccharide-based delivery platforms in cancer theranostics to transform patient outcomes.
dc.identifier.citationSivakumar, P. M., Zarepour, A., Akhter, S., Perumal, G., Khosravi, A., Balasekar, P., & Zarrabi, A. (2025). Anionic polysaccharides as delivery carriers for cancer therapy and theranostics: An overview of significance. International Journal of Biological Macromolecules, 294, 139211.
dc.identifier.doi10.1016/j.ijbiomac.2024.139211
dc.identifier.endpage27
dc.identifier.issn0141-8130
dc.identifier.issn1879-0003
dc.identifier.pmid39732249
dc.identifier.scopus2-s2.0-85214344435
dc.identifier.startpage1
dc.identifier.urihttp://dx.doi.org/10.1016/j.ijbiomac.2024.139211
dc.identifier.urihttps://hdl.handle.net/20.500.12713/6209
dc.identifier.volume294
dc.identifier.wosWOS:001414581000001
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorZarrabi, Ali
dc.institutionauthoridAli Zarrabi / 0000-0003-0391-1769
dc.language.isoen
dc.publisherElsevier b.v.
dc.relation.ispartofInternational journal of biological macromolecules
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectAnionic Polysaccharides
dc.subjectBiopolymer
dc.subjectCancer Nanomedicine
dc.subjectTargeted Drug Delivery
dc.subjectTheranostics
dc.titleAnionic polysaccharides as delivery carriers for cancer therapy and theranostics: An overview of significance
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
1-s2.0-S0141813024100220-main.pdf
Boyut:
12.48 MB
Biçim:
Adobe Portable Document Format
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.17 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama: